Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins

Journal of Pharmaceutical Sciences

Volumn 101, Issue 8, 2012, Pages 2900-2908

  Jia, Junting ^a   Xiao, Yan ^a   Liu, Jianping ^a   Zhang, Wenli ^a   He, Hongliang ^a   Chen, Liang ^a   Zhang, Mengyuan ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cancer chemotherapy; Discoidal rHDLs; LCAT; Lipids lipoproteins; Paclitaxel; Particle size; Physical stability; Remodeling; Structure; Targeted drug delivery; Transformation

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LIPOID S 100; LIPOSOME; PACLITAXEL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; RECOMBINANT HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; PARTICLE SIZE;

EID: 84862842139     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23210     Document Type: Article

References (36)

1. Liang HQ, Rye KA, Barter PJ. 1996. Remodelling of reconstituted high density lipoproteins by lecithin: Cholesterol acyltransferase. J Lipid Res 37(9):1962-1970.
2. Rader DJ. 2006. Molecular regulation of HDL metabolism and function: Implications for novel therapies. J Clin Invest 116(12):3090-3100.
3. Rensen PCN, de Vrueh RLA, Kuiper J, Bijsterbosch MK, Biessen EAL, van Berkel TJC. 2001. Recombinant lipoproteins: Lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47(2-3):251-276.
4. Skajaa T, Cormode DP, Falk E, Mulder WJM, Fisher EA, Fayad ZA. 2010. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol 30(2):169-176.
5. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. 2010. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 18(1):53-58.
6. Cho KH. 2009. Biomedicinal implications of high-density lipoprotein: Its composition, structure, functions, and clinical applications. BMB Rep 42:393-400.
7. Lacko AG, Nair M, Prokai L, McConathy WJ. 2007. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv 4(6):665-675.
8. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. 2008. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19(2):183-188.
9. Chen W, Jarzyna PA, van Tilborg GAF, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJM. 2010. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 24(6):1689-1699.
10. Ng KK, Lovell JF, Zheng G. 2011. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 44 (10):1105-1113.
11. McConathy WJ, Paranjape S, Mooberry L, Buttreddy S, Nair M, Lacko AG. 2011. Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv Transl Res 1(2):113-120.
12. Ryan RO. 2008. Nanodisks: Hydrophobic drug delivery vehicles. Expert Opin Drug Deliv 5(3):343-351.
13. Zhang W, Xiao Y, Liu J, Wu Z, Gu X, Xu Y, Lu H. 2011. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int J Pharm 419(1-2):314-321.
14. Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, Kane J, Krieger M, Zannis VI. 2000. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. J Biol Chem 275(28):21262-21271.
15. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. 2006. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 168(4):1107-1118.
16. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. 2006. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res 47(2):260-267.
17. Jonas A, Wald JH, Toohill K, Krul E, Kezdy K. 1990. Apolipoprotein AI structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. J Biol Chem 265(36):22123.
18. Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD. 2007. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 24(12):2402-2411.
19. Zhang J, Zhang Z, Yang H, Tan Q, Qin S, Qiu X. 2005. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies. Pharm Res 22(4):573-583.
20. Nie S, Hsiao WLW, Pan W, Yang Z. 2011. Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: In vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine 6:151-166.
21. Kistler P, Nitschmann H. 1962. Large scale production of human plasma fractions. Vox Sang 7(4):414-424.
22. Wang L, Chen WZ, Wu MP. 2010. Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1cells and improves the plasma HDL inflammatory index. Cytokine 49(2):194-200.
23. Jain SK, Chaurasiya A, Gupta Y, Jain A, Dagur P, Joshi B, Katoch VM. 2008. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 25(5):289-297.
24. Holmquist L. 2002. Selective extraction of lecithin: Cholesterol acyltransferase (EC 2.3. 1.43) from human plasma. J Biochem Biophys Methods 52(1):63-68.
25. Parks J, Gebre A. 1997. Long-chain polyunsaturated fatty acids in the sn-2 position of phosphatidylcholine decrease the stability of recombinant high density lipoprotein apolipoprotein AI and the activation energy of the lecithin: Cholesterol acyltransferase reaction. J Lipid Res 38(2):266-275.
26. Vaziri N, Liang K, Parks J. 2001. Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 280(5):F823-F828.
27. Zhang J. 2007. A study of the effects of quercetin on the expression of HMGCR and the cholesterol synthesis of HL-02 cells. Zhonghua Gan Zang Bing Za Zhi 15(2):143-145.
28. Tufteland M, Ren G, Ryan RO. 2008. Nanodisks derived from amphotericin B lipid complex. J Pharm Sci 97(10):4425-4432.
29. Shi Y, Kim S, Huff TB, Borgens RB, Park K, Shi R, Cheng JX. 2009. Effective repair of traumatically injured spinal cord by nanoscale block copolymer micelles. Nat Nanotechnol 5(1):80-87.
30. Gessner A, Lieske A, Paulke BR, Müller RH. 2002. Influence of surface charge density on protein adsorption on polymeric nanoparticles: Analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm 54(2):165-170.
31. Guo L, Hamilton RL, Goerke J, Weinstein JN, Havel RJ. 1980. Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. J Lipid Res 21(8):993-1003.
32. Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, Niimi M, Miyauchi A, Wong NCW, Ishida T. 2004. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 64(4):1515-1521.
33. Kim JH, Kim YS, Kim S, Park JH, Kim K, Choi K, Chung H, Jeong SY, Park RW, Kim IS. 2006. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J Control Release 111(1-2):228-234.
34. Roosbeek S, Vanloo B, Duverger N, Caster H, Breyne J, De Beun I, Patel H, Vandekerckhove J, Shoulders C, Rosseneu M. 2001. Three arginine residues in apolipoprotein AI are critical for activation of lecithin: Cholesterol acyltransferase. J Lipid Res 42(1):31-40.
35. Nobecourt E, Davies M, Brown B, Curtiss L, Bonnet D, Charlton F, Januszewski A, Jenkins A, Barter P, Rye KA. 2007. The impact of glycation on apolipoprotein AI structure and its ability to activate lecithin: Cholesterol acyltransferase. Diabetologia 50(3):643-653.
36. Bielicki JK, Forte TM. 1999. Evidence that lipid hydroperoxides inhibit plasma lecithin: Cholesterol acyltransferase activity. J Lipid Res 40(5):948-954.